Expert analysis: the importance of testing in Crohn’s disease and colitis

Living With Cancer: Should you consider lung cancer screening?
December 11, 2018
I Have Rheumatoid Arthritis,” says Tennis Champ Caroline Wozniaki
December 11, 2018
Show all

Expert analysis: the importance of testing in Crohn’s disease and colitis

The diagnosis of Crohn’s disease (CD) does not rely on a single gold standard but requires the integration of clinical data with endoscopic, histologic, radiological and biochemical investigations.

The diagnosis of Crohn’s disease (CD) does not rely on a single gold standard but requires the integration of clinical data with endoscopic, histologic, radiological and biochemical investigations.1
Biomarkers have become essential to discriminate CD from ulcerative colitis (UC), to grade the severity of inflammation because symptoms based scores are subjective, to measure the response to pharmacological options, to predict the risk of relapse and to monitor for postoperative recurrence.2
While erythrocyte sedimentation rate should be abandoned because of its low specificity, being also affected by haematocrit and physiological states such as pregnancy and age, C-reactive protein and faecal calprotectin (FC) are now widely used.
CRP is produced by hepatocytes in response to proinflammatory cytokines, chiefly interleukin-6 (IL-6), tumour necrosis factor alpha (TNF-alpha) and IL-1beta, and has a short half-life of about 19 hours, making it a more responsive indicator of acute inflammation. Meta-analyses have shown its role in the differential diagnosis between IBD and IBS and the correlation with endoscopic findings; however, specificity is low and about 25% of patients with active CD on endoscopy do not express levels of CRP above the normal threshold because of genetic variants.
FC is a neutrophil-derived protein excreted in the faeces and is a more reliable surrogate marker of inflammation, with a significant correlation with endoscopy. FC predicts mucosal healing and response to anti-TNF therapy, and has a prognostic role for disease course, even in the postoperative setting.3 There are, however, potential barriers in implementing its use in clinical practice as compared with CRP: patients’ dis-inclination to collect stools, lack of specificity as opposed to other infectious or inflammatory processes of the gut, different accuracy according to disease type (CD vs UC) and location (colitis vs enteritis), need for standardisation due to variability among different assays, and different cutoff thresholds depending upon the clinical scenario.
STRIDE vs CALM
Although the recommendations of the STRIDE consensus4 do not recognise biomarkers as a target for therapies, considering them as adjunctive measures for inflammation, the CALM study,5 which compares two different strategies in the management of CD with adalimumab, suggests a revision of these guidelines by incorporating FC as a treatment target. This study analyses treatment outcomes in two different groups, the first adopting a conventional strategy using only clinical criteria to guide escalation of therapy; the other, the tight control group, adopting biomarkers and especially FC to drive treatment optimisation. The tight control group had a significantly improved outcome. Self-monitoring at home of FC by a rapid test and the use of dedicated smartphones opens the door to a new way of monitoring the patients through telemedicine.6
Read on: Expert analysis: the importance of testing in Crohn’s disease and colitis

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.